Asklepios Kliniken Hamburg GmbH
- Address
- lock Available on a paid plan
Asklepios Kliniken Hamburg GmbH - Comprehensive Oncology and Cardiovascular Research Center
Asklepios Kliniken Hamburg GmbH stands as a leading European research institution with extensive expertise in advanced cancer therapeutics and precision medicine. The center demonstrates particular strength in investigating novel targeted therapies and immunotherapies across a diverse spectrum of malignancies, from solid tumors to hematologic cancers. Their research portfolio encompasses cutting-edge trials evaluating HER2-targeted agents, immune checkpoint inhibitors, and CAR-T cell therapies in multiple cancer types.
- Advanced lung cancer research, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with focus on immunotherapy combinations and targeted agents for EGFR mutations
- Hematologic malignancies including multiple myeloma, acute myeloid leukemia (AML), and lymphomas (Hodgkin lymphoma, mantle cell lymphoma, primary CNS lymphoma)
- Gastrointestinal cancers spanning pancreatic, colorectal, biliary tract, and hepatocellular carcinomas with emphasis on novel combination therapies
- Genitourinary cancers including urothelial carcinoma, renal cell carcinoma, and rare malignancies such as anal canal carcinoma and testicular seminoma
The center's research extends beyond oncology into cardiovascular medicine, with trials investigating renal denervation for hypertension, aortic valve stenosis progression, and acute coronary syndrome management. Their multidisciplinary approach integrates advanced molecular diagnostics including minimal residual disease (MRD) monitoring, circulating tumor DNA (ctDNA) assessment, and biomarker-driven patient selection. The institution actively participates in international multicenter collaborations, contributing to pivotal trials that shape treatment standards across multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 174 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 168 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 45 by active trials.
- 1AstraZeneca AB6active
lock +44 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +22 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Asklepios Kliniken Hamburg GmbH
lock Showing 1 of 126 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer | Bristol-Myers Squibb Services Unlimited Company | Phase III | Not Recruiting | May 2017 | Jul 2025 |
IMP list
lock Showing 1 of 174 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 20 | Unknown | 2015-11-20 | 2026-06-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.